Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 14: Sickle Cell Trait
- Other version(s) of this article
-
You are viewing the most recent version of this article. Previous versions:
-
Introduction
Sickle cell trait (SCT), in which a normal hemoglobin gene and an abnormal mutated β-globin sickle gene (HbS) are inherited, occurs in 8% of blacks in the United States (0.08% of nonblacks).1,2 SCT has been regarded as a benign condition that generally does not expose affected people to health risks, although for many years it has also been recognized as a potential cause of death in military training recruits during vigorous and intense physical exertion.3 More recently, evidence has been assembled proposing SCT as a cause of sudden death in competitive athletes, usually during training and conditioning.4,5 In 2010, the National Collegiate Athletic Association (NCAA) mandated SCT screening (with solubility testing) for all student-athletes in division I sports (division II, 2012; division III, 2013). In addition, all newborns have been routinely tested for SCT shortly after birth since 1987 in accordance with a National Institutes of Health recommendation.1,6 Much of the controversy regarding SCT and athletes has focused on mandatory screening measures for the genetic defect, an issue that we have not addressed in this statement.
That SCT can be responsible for lethal sudden collapse,7 including on the athletic field, is based on evidence from the forensic-based US National Sudden Death in Athletes Registry4,8,9 and other databases,10 as well as numerous case reports and considerable expert experience acquired in athletic venues.5 The epidemiology and characterization of SCT-related events in athletes are evolving. A large experience from the US Sudden Death in Athletes Registry documented SCT-associated collapse and death in 0.9% of 2462 athletes. This outcome occurred in 3.3% of the blacks in the registry.4 Ages of the victims were 12 to 22 years, and 90% were male. Events were most common in college football players during conditioning drills.
A distinctive clinical presentation has emerged that involves gradual deterioration over several minutes. Symptoms include cramping, dyspnea, muscle pain and severe weakness, and fatigue and exhaustion, provoked by vigorous physical exertion, often with sequential brief bursts of sustained maximal physical activity (eg, interval training). Events typically occur early in the training season or after periods of deconditioning, often in ambient temperatures ≥80°, at high altitude, or associated with development of rhabdomyolysis.4,11–14 Notably, this scenario is in striking contrast to collapse caused by cardiovascular disease with ventricular tachyarrhythmias, which is typically virtually instantaneous.8,9
Although the pathophysiology and clinical determinants of death in people with SCT participating in intense exercise are not fully understood, cardiovascular collapse likely occurs under conditions that (in laboratory studies) promote HbS polymerization and erythrocyte sickling. These include hyperthermia, dehydration, acidosis, and hypoxemia.11–14 It is possible that with intense exercise, a cascade of events ensues under unpredictable circumstances that recreates some of the laboratory conditions that lead to HbS polymerization and erythrocyte sickling, thereby triggering vascular occlusion, endothelial damage, and impaired muscular blood flow.12–16 This exertional sickling scenario could promote rhabdomyolysis and disseminated intravascular coagulation, which in turn could lead to hyperkalemia, lactic acidosis, worsening hypoxia, impaired cardiac and renal function, and lethal arrhythmias. However, widespread sickling in the heart and other organs identified at autopsy does not itself represent definitive evidence for SCT-related death, because postmortem HbS polymerization and erythrocyte sickling are an expected consequence of the diminished oxygen environment at death.
These considerations have advanced specific precautionary recommendations for targeted and tailored measures during training for athletes with SCT to enhance the prevention of sudden death.15,16 These precautions, which can also benefit all athletes, include more gradual conditioning at the beginning of the training season (or after periods of deconditioning) with attention to modifying pace, providing adequate rest and hydration during conditioning drills, and promoting a high index of suspicion to immediately cease physical activity should muscle weakness, cramping or pain, fatigue, and disproportionately excessive dyspnea occur.
Indeed, collapse of an athlete with SCT is a medical emergency that requires support of vital signs, administration of supplemental oxygen, intravenous hydration, possibly cooling to protect against fulminating rhabdomyolysis, and likely rapid transport to a medical facility. A metabolic insult with lactic acidosis, hyperkalemia, and hypocalcemia can lead to pulseless electrical activity, so that the effectiveness of external defibrillation in this clinical setting is unpredictable. Such modified conditioning strategies and surveillance are now widely used by athletic trainers and coaching staffs in college athletic programs to prevent SCT-related complications and catastrophes.
SCT should now be included among the myriad of nontraumatic risks of sports participation capable of leading to the demise of some susceptible athletes, the vast majority of whom are black.
Recommendations
Recognition of SCT status is not itself a justification for disqualification from competitive sports (Class I; Level of Evidence C).
Recommended preventive strategies (including adequate rest and hydration) should be performed to minimize the likelihood of an event occurring on the athletic field in a person known to have SCT (Class I; Level of EvidenceB).
It is critical to be prospectively aware of acute emergency medical strategies should suspicion of an emerging event arise in an athlete known to have SCT (Class I; Level of Evidence C).
Particular caution should be exercised for athletes known to have SCT who are competing or training in high environmental temperatures or at extreme altitude (Class I; Level of Evidence C).
Disclosures
Writing Group Member | Employment | Research Grant | Other Research Support | Speakers’ Bureau/Honoraria | Expert Witness | Ownership Interest | Consultant/Advisory Board | Other |
---|---|---|---|---|---|---|---|---|
Barry J. Maron | Minneapolis Heart Institute Foundation | None | None | None | None | None | None | None |
E. Randy Eichner | University of Oklahoma | None | None | None | None | None | None | None |
Kevin M. Harris | Minneapolis Heart Institute Foundation | None | None | None | None | None | None | None |
Martin H. Steinberg | Boston University | None | None | None | None | None | None | None |
Paul D. Thompson | Hartford Hospital | None | None | None | None | None | None | None |
Reviewer | Employment | Research Grant | Other Research Support | Speakers’ Bureau/Honoraria | Expert Witness | Ownership Interest | Consultant/Advisory Board | Other |
---|---|---|---|---|---|---|---|---|
Michelle A. Grenier | University of Mississippi | None | None | None | None | None | None | None |
Pranav Kansara | Christiana Care Health System | None | None | None | None | None | None | None |
Mark S. Kindy | Medical University of South Carolina | None | None | None | None | None | None | None |
Footnotes
References
- 1.
Steinberg MH. In the clinic: sickle cell disease.Ann Intern Med. 2011; 155:ITC31–315. doi: 10.7326/0003-4819-155-5-201109060-01003.CrossrefMedlineGoogle Scholar - 2.
Goldsmith JC, Bonham VL, Joiner CH, Kato GJ, Noonan AS, Steinberg MH. Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications.Am J Hematol. 2012; 87:340–346. doi: 10.1002/ajh.22271.CrossrefMedlineGoogle Scholar - 3.
Kark JA, Posey DM, Schumacher HR, Ruehle CJ. Sickle-cell trait as a risk factor for sudden death in physical training.N Engl J Med. 1987; 317:781–787. doi: 10.1056/NEJM198709243171301.CrossrefMedlineGoogle Scholar - 4.
Harris KM, Haas TS, Eichner ER, Maron BJ. Sickle cell trait associated with sudden death in competitive athletes.Am J Cardiol. 2012; 110:1185–1188. doi: 10.1016/j.amjcard.2012.06.004.CrossrefMedlineGoogle Scholar - 5.
Eichner ER. Sickle cell trait in sports.Curr Sports Med Rep. 2010; 9:347–351. doi: 10.1249/JSR.0b013e3181fc73d7.CrossrefMedlineGoogle Scholar - 6.
Bonham VL, Dover GJ, Brody LC. Screening student athletes for sickle cell trait: a social and clinical experiment.N Engl J Med. 2010; 363:997–999. doi: 10.1056/NEJMp1007639.CrossrefMedlineGoogle Scholar - 7.
Taylor C, Kavanagh P, Zuckerman B. Sickle cell trait: neglected opportunities in the era of genomic medicine.JAMA. 2014; 311:1495–1496. doi: 10.1001/jama.2014.2157.CrossrefMedlineGoogle Scholar - 8.
Maron BJ. Sudden death in young athletes.N Engl J Med. 2003; 349:1064–1075. doi: 10.1056/NEJMra022783.CrossrefMedlineGoogle Scholar - 9.
Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006.Circulation2009; 119:1085–1092. doi: 10.1161/CIRCULATIONAHA.108.804617.LinkGoogle Scholar - 10.
Harmon KG, Drezner JA, Klossner D, Asif IM. Sickle cell trait associated with a RR of death of 37 times in National Collegiate Athletic Association football athletes: a database with 2 million athlete-years as the denominator.Br J Sports Med. 2012; 46:325–330. doi: 10.1136/bjsports-2011-090896.CrossrefMedlineGoogle Scholar - 11.
Admanski C. Steelers’ Ryan Clark Prominent in Sickle Cell Initiative Launch.CBSSports.com Website. 2012. http://www.cbssports.com/nfl/blog/nfl-rapidreports/20049491/steelers-ryan-clar-prominent-in-sickle-cell-initiative-launch. Accessed March 12, 2013.Google Scholar - 12.
Jones SR, Binder RA, Donowho EM Sudden death in sickle-cell trait.N Engl J Med. 1970; 282:323–325. doi: 10.1056/NEJM197002052820607.CrossrefMedlineGoogle Scholar - 13.
Eichner ER. Sickle cell considerations in athletes.Clin Sports Med. 2011; 30:537–549. doi: 10.1016/j.csm.2011.03.004.CrossrefMedlineGoogle Scholar - 14.
Tsaras G, Owusu-Ansah A, Boateng FO, Amoateng-Adjepong Y. Complications associated with sickle cell trait: a brief narrative review.Am J Med. 2009; 122:507–512. doi: 10.1016/j.amjmed.2008.12.020.CrossrefMedlineGoogle Scholar - 15. The National Athletic Trainers’ Association (NATA) releases “Sickle Cell Trait and the Athlete” consensus statement [news release]. Dallas, TX: National Athletic Trainers’ Association; June 27, 2007. http://www.nata.org/NR062107. Accessed April 17, 2012.Google Scholar
- 16.
Klossner D. 2009–10 NCAA Sports Medicine Handbook. Indianapolis, IN: National Collegiate Athletic Association; 2009. http://www.ncaapublications.com/productdownloads/MD10.pdf. Accessed May 3, 2011.Google Scholar
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.